Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage

- August 9th, 2018

Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the United States Food and Drug Administration has granted clearance for Athenex Pharmaceutical Division to import Potassium Chloride Injection Concentrate (2 mEq/mL) in response to a national drug shortage of that … Continued

Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the United States Food and Drug Administration has granted clearance for Athenex Pharmaceutical Division to import Potassium Chloride Injection Concentrate (2 mEq/mL) in response to a national drug shortage of that product.

As quoted in the press release:

This FDA clearance allows APD to import Potassium Chloride Injection Concentrate on a temporary basis or for the duration of the shortage.

Jeffrey Yordon, Athenex’s Chief Operating Officer and President of Athenex’s Pharmaceutical Division, stated, “Potassium Chloride is currently on the drug shortage list of the FDA. We are happy to help provide a solution to the current shortage as we remain focused on developing novel therapies for the treatment of cancer.” The importation of Potassium Chloride Injection began in August, 2018 and is currently helping supply the US market demand.

Click here to read the full press release.

Biotech Stocks in 2018

 
Find out how the market will look this year

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *